Cross-Border Dealflow Is Concentrating Around Three Corridors

The Geography of Deals Has Narrowed

A decade ago, cross-border biopharma transactions were scattered. A Danish biotech could out-license to a Korean pharma. A Brazilian generics company could pick up a Canadian asset. It happened, but the pattern was noise.

That's changed. The transactions we track increasingly funnel through three dominant corridors: US-Europe, US-China, and US-Japan. Each has its own structural logic, its own risk-sharing preferences, and its own valuation dynamics. If you're a clinical-stage company preparing for a licensing process, understanding which corridor your asset fits — and what the buyer on the other end expects — is no longer optional context. It's the starting point.

US-Europe: The Mature Corridor Gets More Competitive

The US-Europe corridor remains the deepest and most active channel for biopharma dealmaking globally. It runs in both directions. European biotechs — particularly from the UK, Switzerland, Germany, and the Nordics — continue to out-license to US-based pharma and large-cap biotech. Simultaneously, US companies with global ambitions partner with European firms for regional development and commercialization rights.

What's shifted in 2025 and into 2026 is the competitive intensity. European acquirers — Novo Nordisk, Roche, AstraZeneca — are bidding more aggressively for US-origin assets, especially in cardiometabolic and oncology. AstraZeneca's continued acquisition spree and Novo's expansion beyond GLP-1s have created bidding pressure that didn't exist three years ago.

For founders, this is good news. Multiple credible bidders on both sides of the Atlantic mean better terms. But it also means more process complexity. European acquirers tend to want broader territorial rights than their US counterparts, and they're more likely to push for worldwide licenses. US pharma, by contrast, is often comfortable carving out Europe or ex-US rights. Know this before your first call.

Structurally, US-Europe deals tend to feature higher upfronts relative to total deal value compared to Asia-origin corridors. Milestone schedules lean toward regulatory and commercial events rather than development milestones. Royalty rates in this corridor have been creeping upward, reflecting competition for quality assets.

US-China: Structural Reset After the Policy Shock

The US-China corridor looked like it might collapse in 2024. The BIOSECURE Act, while narrowly targeted at CDMOs, sent a chilling signal through the broader US-China biopharma relationship. Chinese biotechs saw their partnerships scrutinized. US pharma BD teams got cautious. The number of new out-licensing deals from China to the US slowed meaningfully.

Now, in mid-2026, the picture is more nuanced. The corridor hasn't disappeared — it's restructured. Chinese biotechs with genuinely differentiated clinical-stage assets — particularly in oncology and immunology — are still finding US partners. But the terms have shifted. Upfronts as a percentage of total deal value have compressed. Milestone-heavy structures dominate. And US acquirers are increasingly insisting on data packages and regulatory strategies that are explicitly designed for FDA pathways, not NMPA-first approaches.

The AbbVie/LaNova deal earlier this year was instructive. AbbVie paid a notable upfront for a bispecific antibody program, but the milestone structure was heavily back-loaded toward US-specific regulatory and commercial events. That's the template now.

For Chinese biotechs looking to out-license to the US, the message is clear: lead with your US regulatory strategy, not your China data. And expect that your upfront will be lower than what a comparable European or Japanese asset might command. The geopolitical discount is real, and it's priced into every term sheet.

US-Japan: Quiet Volume, Premium Terms

The US-Japan corridor gets less attention than it deserves. Japanese pharma companies — Astellas, Daiichi Sankyo, Takeda, Eisai — have been among the most consistent acquirers and licensors of US-origin assets over the past several years. Daiichi Sankyo's ADC partnership with AstraZeneca for Enhertu remains one of the highest-value biopharma collaborations in history.

What distinguishes this corridor is the quality of the terms. Japanese acquirers tend to pay premium upfronts relative to asset stage. They're patient capital — comfortable with longer development timelines and less likely to trigger termination clauses at the first sign of a Phase 2 data wobble. They also tend to structure deals with Japan-specific territorial carve-outs, which can be valuable for founders who want to retain rights in other major markets.

The flip side: Japanese deal processes are slower. Expect longer diligence timelines, more internal consensus-building, and a preference for existing relationships. Cold outreach to Japanese pharma BD teams converts at a lower rate than equivalent outreach to US or European counterparts. Warm introductions and repeat interactions at conferences like BIO and JPM matter more here than anywhere else.

For US biotechs with assets in oncology, neuroscience, or rare disease, running a parallel process that includes Japanese pharma is increasingly a best practice. The premium terms can create competitive tension that lifts the entire deal.

What the Corridor Data Means for Deal Structure

The structural differences across corridors are not subtle. They affect every major term: upfront size, milestone allocation, royalty rates, territorial scope, and governance provisions.

In the US-Europe corridor, deals tend to feature worldwide or ex-Asia rights with relatively balanced milestone schedules. In the US-China corridor, milestone-heavy structures with development-stage gates dominate, and territorial scope is narrowing to US or North America rights. In the US-Japan corridor, Japan-only or Asia-Pacific rights are common, but the per-territory value tends to be higher.

These benchmarks are available in real-time on Solidus, our deal terms platform.

Governance is another divergence point. European and US acquirers generally accept joint steering committee structures with reasonable decision-making provisions. Japanese acquirers are more likely to accept licensor-favorable governance in exchange for clearer exclusivity protections. Chinese licensees of US assets — a less common but emerging pattern — tend to want more operational control over development in their territory.

Implications

If you're a clinical-stage biotech founder preparing for a licensing process, your geographic strategy should be explicit — not an afterthought. Identify which corridor your asset naturally fits. An oncology ADC will attract interest across all three corridors. A rare neurological disease asset will pull strongest in US-Europe and US-Japan. A biosimilar or fast-follower will find its best home in US-China, despite the headwinds.

Run your process accordingly. If Japanese pharma is a realistic counterparty, start those conversations early — six to nine months before you want a term sheet, not six weeks. If you're a China-origin biotech targeting US partners, invest in your FDA regulatory narrative before you invest in your deal deck. The upfront discount for China-origin assets is real, but it narrows significantly for companies with clear US clinical strategies and IND-stage or later data packages.

For investors evaluating portfolio company exit paths, corridor selection affects expected returns. A US-Japan out-licensing deal may yield a higher upfront than a comparable US-China deal, even for a similar-stage asset. Factor this into your valuation models. And for pharma BD teams: the corridors are getting crowded. The differentiation is no longer "we'll do a deal with you" — it's the speed, governance terms, and territorial flexibility you can offer. In a seller's market for quality clinical assets, the buyer who moves fastest and structures most creatively will win.